What Cardinol LA Treats: Main Uses and Benefits

Cardinol LA, the extended-release formulation of propranolol, is a medication generally applied in clinical settings that involve long-term management of physiological responses to support stability across several symptomatic domains. This medication is used across domains where additional symptomatic support is needed.

---

Sustained Control and Prophylactic Relief

Cardinol LA is used for managing conditions marked by increased physiological stress, such as essential hypertension (high blood pressure) and stable angina pectoris (recurrent chest discomfort). It is commonly used to help with prophylaxis for recurrent migraine headaches and to manage the symptoms of essential tremor (involuntary shaking). Furthermore, it is applied in addressing symptoms of heightened physiological activity, such as those linked to an overactive thyroid (thyrotoxicosis).

This medication helps address symptom clusters that create noticeable physiological strain, particularly those associated with irregular heart rhythms and severe, episodic pain. This supportive relief may assist with maintaining functional stability and contributes to improved comfort during periods of heightened symptoms.

“This continuous therapeutic support plays a role in managing the overall workload on the heart and may assist with maintaining functional stability over time.”

---

Quick Fact Block

Quick Fact: Relief for Key Symptom Domains
Supports stability in chronic conditions like high blood pressure and recurrent angina.
Assists with maintaining comfort during episodic pain from migraine headaches.
Helps manage involuntary shaking (tremor) and physical signs of systemic imbalance.

Eligibility Map: Who Can and Cannot Use Cardinol LA

This eligibility profile for Cardinol LA (Propranolol Extended-Release) is defined by governmental regulatory documents and outlines specific population restrictions and contraindications.

Eligibility Scope

Classification	Restricted Population/Condition
Absolute Contraindications	Patients with Cardiogenic Shock, Decompensated Heart Failure, Bronchial Asthma, Sinus Bradycardia, or Second/Third Degree Heart Block (unless a pacemaker is present). Also prohibited for those with Metabolic Acidosis or severe Peripheral Arterial Circulatory Disturbances.
Not Recommended	Pediatric patients (under 18 years) are generally not recommended due to a lack of established pharmacokinetic data for the extended-release form.
Caution Required	Patients with Hepatic Impairment (e.g., cirrhosis) and Renal Impairment must use the medicine with caution, as dose reduction may be necessary. Caution is also required in patients with Diabetes Mellitus or Thyrotoxicosis, as the medicine may mask key physical signs of these conditions.
Reproductive Status	Use during pregnancy requires monitoring of the neonate for specific effects. The active ingredient is excreted in breast milk, but studies suggest minimal risk to the infant.

Cardinol LA's interaction profile is officially defined by its metabolic pathways and potential for additive pharmacodynamic effects. Co-administration with Verapamil or Diltiazem is a formal contraindication due to the documented risk of severe hypotension and cardiac failure. Similarly, neither should be administered intravenously within 48 hours of discontinuing Cardinol LA.

The drug is metabolized through multiple Cytochrome P450 enzymes, notably CYP2D6, CYP1A2, and CYP2C19. Regulatory data documents that inhibitors of these enzymes, such as Quinidine and Propafenone, increase systemic exposure and plasma concentrations, while inducers like Rifampin decrease them. Cigarette smoking is also documented to induce hepatic clearance, resulting in lower plasma levels.

Other clinically significant interactions include a potential reduction in antihypertensive activity when co-administered with NSAIDs. A pharmacodynamic caution exists with Digitalis glycosides and Catecholamine-Depleting Drugs due to the risk of additive cardiac depression and marked bradycardia. For timing-based constraints, the beta-blocker must be withdrawn several days before Clonidine to minimize the risk of rebound hypertension, and administration should be separated from Antacids (containing Aluminum Hydroxide) by two hours to prevent reduced absorption. An interaction-related risk of hypoglycaemia is specifically noted for patients with chronic liver disease.

Beta-Receptor Blockade and Cardiac Dampening

Cardinol LA functions as a non-selective antagonist by binding to and blocking both beta1 and beta2 adrenergic receptors across the body. This prevents the binding of endogenous catecholamines, such as norepinephrine and epinephrine. This molecular action decreases sympathetic signaling to the heart, resulting in reduced heart rate (negative chronotropy) and reduced contractile force (negative inotropy).

Modulating Systemic Regulator Pathways

The mechanism extends to the kidneys, where beta1 receptor antagonism on juxtaglomerular cells blocks sympathetic-mediated renin release. Inhibition of renin release disrupts the Renin-Angiotensin-Aldosterone System (RAAS) cascade, which results in lower systemic levels of the vasoconstrictor angiotensin II and reduced aldosterone action.

Central Sympathetic Signal Attenuation

The drug's lipophilicity enables it to cross the blood-brain barrier and modulate beta-receptors within the Central Nervous System (CNS). This activity reduces the central drive for catecholamine release and affects the somatic responses to adrenergic signaling.

Cardinol LA, the extended-release formulation of propranolol hydrochloride, is approved exclusively for oral administration and is always taken as a whole capsule. The capsule must not be broken, crushed, or chewed, as this action compromises the long-acting mechanism designed for sustained release over time. This medicine is designed for a once-daily dosing pattern.

Treatment is typically initiated at a dose of 80 mg once daily for most uses, with the dose then gradually increased by a healthcare professional at defined intervals, often over three to seven days, to establish an appropriate maintenance dose. Maintenance doses commonly range from 120 mg to 160 mg once daily, although specific conditions like portal hypertension may require a dose adjusted to achieve a measurable 25% reduction in resting heart rate.

For administration, the capsule should be taken at the same time each day and may be taken either consistently with food or consistently without food. If a dose is missed, the typical procedure is to skip the missed dose and return to the normal schedule if it is close to the time for the next dose; taking two doses at once is prohibited. When discontinuing chronic therapy, the dosage must be gradually tapered over a period of one to two weeks to avoid abrupt changes. Furthermore, older adults should begin treatment at the lowest available dose, and caution is advised when dosing patients with hepatic or renal impairment due to potential changes in drug clearance.

Research evidence / Overview of studies for Cardinol LA

Research exploring Cardinol LA for Conditions characterized by functional limitations

The initial research for Cardinol LA was studied for conditions marked by functional limitations. These studies explored how symptoms and daily function change over time in observed populations. The research contexts primarily involved observational settings evaluating daily-life functioning and included people reporting various degrees of discomfort. The outcomes monitored were mostly patient-reported outcomes describing perceived discomfort and outcomes reflecting daily functioning or activity level. In these initial settings, the data show patterns related to how the subjects' reported discomfort evolved in the observed populations during the study period.

These studies suggest that for some groups, patterns were observed related to the frequency of episodes related to physical discomfort. The findings describe patterns observed in the studies where individuals reported changes in their overall activity level. However, the evidence is not definitive. The findings were mixed across different groups, and the results apply only to the populations studied. Furthermore, the follow-up durations were limited, typically lasting only a few weeks. Because of this, long-term effects are not fully established, and certainty remains low when considering broad applicability.

Research exploring Cardinol LA for Conditions involving periods of heightened symptoms

Research has also examined Cardinol LA in conditions involving periods of heightened symptoms, or acute and disruptive episodes. These studies were conducted during periods of increased symptom activity to specifically evaluate episodic or acute changes. This research focused on subjects who were experiencing fluctuating or unstable symptoms. The primary goal was evaluated in trials assessing short-term changes during these active phases. Outcomes capturing phases of heightened symptom activity and outcomes linked to inflammatory or irritative states were the main areas of interest.

Studies reported how symptoms evolved in the observed populations when measured during these defined time intervals. The research describes that for some individuals, there were measured changes in the intensity of the reported symptoms during an episode. Cardinol LA was observed in some studies to be associated with changes in how symptoms are measured in the short term. The findings indicate that the research highlights changes measured during the study period and provides context regarding how patients reported their experience.

General limitations and knowledge gaps

It is important to understand the overall picture of the evidence. Evidence quality varies across studies, and much of the current data is derived from studies focusing on episodes where symptoms become more noticeable. The available research was associated with specific conditions and measured short-term outcomes. The study results reflect the specific conditions under which they were conducted, and findings describe group patterns, not personal outcomes. Data are still emerging, and to draw stronger conclusions, further research that includes larger groups and longer periods of observation is needed.

Key Studies & References

1. Summaries of Clinical Trial Results for Laypersons (EU CT Regulation Annex V Template and Guidance)
2. Chapter 10: Systematic reviews and meta-analysis - ENCePP Methodological Guide

Common questions about Cardinol LA (FAQ)

---

Q: What is the main reason doctors prescribe Cardinol LA?

Official documents indicate that Cardinol LA is approved to manage and treat conditions such as high blood pressure (hypertension) and chest pain (angina pectoris). It is also officially approved for the prevention of migraine headaches. These uses are based on the medicine's ability to help regulate the cardiovascular system.

Q: Does taking Cardinol LA mean I have to avoid certain foods?

While most foods do not pose a direct interaction risk, official product information advises caution with protein-rich foods, as they may increase the amount of the medicine in the blood. Regulatory guidance indicates the capsule should be taken consistently, either always with food or always without food.

Q: How long does the effect of Cardinol LA last in the body?

Cardinol LA is formulated as an extended-release (LA) capsule, which is designed for a sustained and steady release of the medicine over a prolonged time. This delivery mechanism supports its once-daily dosing pattern, aiming to provide continuous therapeutic effects throughout the day.

Q: Is Cardinol LA suitable for people who have kidney issues?

Official product information advises that caution should be exercised when the medicine is used by individuals with kidney disease (renal impairment). The body may remove the medicine slower than normal, which could potentially increase its effects. Dosage management in this situation is overseen by a healthcare provider.

Q: Are there known effects of Cardinol LA on liver function?

Official warnings advise caution when the medicine is used by individuals with liver disease (hepatic impairment). Because the liver is responsible for breaking down the medicine, impaired function may lead to increased drug levels in the blood. Official documents also note an increased risk of low blood sugar (hypoglycemia) in those with chronic liver disease who use this medication.

Q: Why do some people need to take Cardinol LA for a long time?

The medicine is primarily used for the long-term management of chronic cardiovascular conditions, such as high blood pressure or certain types of chest pain. These conditions require continuous support to maintain stable regulation of the heart and vascular system, making ongoing use appropriate for many patients.

Q: Why do doctors check my [specific body parameter, e.g., heart rate] when I'm on Cardinol LA?

As a beta-blocker, Cardinol LA works by deliberately slowing the heart rate and force of contraction. Monitoring the heart rate is a standard practice that helps healthcare providers ensure the medicine is having the intended physiological effect. It also allows them to manage the risk of severe bradycardia, which is a potentially serious side effect.

Q: Can a person with asthma or COPD take Cardinol LA?

Official prescribing information generally lists this medicine as contraindicated (should not be used) for individuals with bronchial asthma or a history of bronchospasm (severe breathing difficulty). As a non-selective beta-blocker, it carries a risk of potentially worsening breathing function in people with such lung conditions.

Q: What evidence supports the use of Cardinol LA for [Main Condition]?

The approved uses are supported by clinical trials that have evaluated its effectiveness in conditions like high blood pressure and angina pectoris. The studies measured objective outcomes such as changes in heart rate and blood pressure, as well as the reduction in the frequency of angina episodes.

Q: What are the contraindications listed for Cardinol LA in official documents?

Official documents list several conditions where the medicine should not be used, known as contraindications. These include specific heart problems such as severe bradycardia (very slow heart rate) and uncompensated heart failure, as well as bronchial asthma. Furthermore, it is contraindicated for concurrent use with certain medicines like Verapamil or Diltiazem.

Q: What are the official clinical trial results for Cardinol LA?

Clinical trials for the extended-release formulation showed effectiveness in controlling high blood pressure, specifically by influencing pulse rate and blood pressure measurements. Studies also indicated that the medicine was associated with reducing the frequency of angina episodes when compared to a placebo or the standard immediate-release formulation.

Q: Is Cardinol LA the same as other medications used for [Main Condition, e.g., blood pressure]?

No, Cardinol LA is classified as a non-selective beta-blocker (beta-adrenergic receptor antagonist). Official information indicates that medicines used for similar conditions, like high blood pressure, often belong to different pharmacological classes, such as ACE inhibitors or calcium channel blockers.

Q: Is it normal to have mild headaches when first starting Cardinol LA?

Official documents list headaches as a common side effect. This is a recognized occurrence, particularly when beginning treatment. Official guidance notes that resting and ensuring adequate fluid intake are sometimes suggested for managing this discomfort.

Q: Are there any major interactions between Cardinol LA and herbal supplements?

While no comprehensive list of all herbal supplements is provided in regulatory documents, some may affect the liver enzymes that break down this medicine or could produce similar physiological effects. Official guidance emphasizes the importance of discussing the use of herbal remedies with a healthcare provider.

Q: Is it safe to take Cardinol LA if I drink alcohol occasionally?

Official product information suggests discussing the use of alcoholic beverages with a healthcare provider. This is because alcohol may increase the amount of the drug in the blood, which could potentially lead to enhanced effects.

Q: Can Cardinol LA be used by women who might become pregnant?

Official prescribing information indicates that women who are pregnant or planning to become pregnant should discuss this with a healthcare provider. This is because the medicine may cause potentially harmful effects for the baby.

Q: Is there a generic version of Cardinol LA available?

Yes, official records confirm that the FDA has approved generic versions of the extended-release propranolol hydrochloride capsule.

Q: Can Cardinol LA interact with birth control pills?

Official documents note that some hormonal contraceptives, particularly those containing ethinyl estradiol, may increase the concentration of Cardinol LA in the blood. This could potentially enhance the medicine's effects, leading to greater decreases in heart rate and blood pressure.

Q: What is the risk of Cardinol LA causing a serious allergic reaction?

Official warnings state that there is a potential for anaphylactic reactions, which are severe allergic reactions. Furthermore, official information advises that patients taking beta-blockers may become more sensitive to allergens.

Q: Are there restrictions on driving or operating machinery while taking Cardinol LA?

Because the medicine can cause side effects like dizziness or fatigue, official instructions advise against activities like driving or operating heavy machinery until you know how the medicine affects you. This warning is related to the potential for impaired alertness.

Q: How does Cardinol LA differ from other drugs that treat [Main Condition]?

Cardinol LA is classified as a non-selective beta-blocker, meaning it acts on two types of receptors in the body (beta1 and beta2 adrenergic receptors). This is a key difference from other medicines used for similar conditions, which may be selective beta-blockers (acting on only one type) or belong to entirely different drug classes, such as ACE inhibitors.

Q: Is Cardinol LA used to prevent [specific event, e.g., heart attacks]?

Yes, in specific patient populations, official documents state that the medicine can be used to help prevent future cardiac events, including heart attacks and strokes. This is in addition to its use in managing chronic conditions like angina and high blood pressure.

Q: Does official prescribing information mention weight gain as a side effect of Cardinol LA?

Weight gain has been reported in clinical studies associated with the use of the medicine. While it is not always listed as a universally common side effect in official information, its occurrence has been noted, and the amount of weight change varies across individuals.

Q: What should I do if my side effects from Cardinol LA do not go away?

Official guidance suggests that communication with a healthcare provider is appropriate if any side effects are severe or do not go away over time. This includes side effects that worsen or cause significant discomfort.

Q: Is Cardinol LA ever prescribed for conditions other than its main approved uses?

Official information notes that a healthcare provider might prescribe the medicine for other purposes not listed on the official label, which is referred to as 'off-label' use. The decision to use a medicine in this way is made by the healthcare provider.

Q: Can Cardinol LA interact with grapefruit or grapefruit juice?

Some components found in grapefruit juice can inhibit the specific liver enzymes (CYP enzymes) that are responsible for breaking down this medicine. This potential for interference could lead to increased drug levels and enhanced effects. It is important to discuss the consumption of grapefruit products with a healthcare provider.

Q: Why is Cardinol LA sometimes combined with other medications?

The medicine may be used in combination with other drugs to help manage certain complex medical conditions. For example, official contexts note its use to help reduce symptoms related to an overactive thyroid (thyrotoxicosis) or to address other multi-faceted cardiovascular needs.

Q: What warnings exist for Cardinol LA regarding surgery or dental procedures?

Official information states that it is necessary to inform the surgeon, anesthesiologist, or dentist that this medicine is being taken before any surgical or dental procedures. Furthermore, regulatory guidance suggests that chronic beta-blocker therapy should not be routinely stopped before major surgery.

Q: Is Cardinol LA safe for children or adolescents?

The safety and effectiveness of the extended-release capsule formulation have not been established for the general population of children and adolescents. It is important to note that a different oral liquid form of the active ingredient is approved for use in infants for specific conditions.

How to Store and Dispose of Cardinol LA

Official regulatory guidelines establish specific requirements for storing, handling, and disposing of Cardinol LA (Propranolol LA) to maintain product stability and ensure public safety.

Storage and Handling Requirements

Requirement Type	Official Statement
Temperature	Store at or below 30 C (Controlled Room Temperature).
Protection	Protect the medicine from moisture and light.
Environment	Keep out of direct heat; do not store in environments like a car or near a window.
Packaging	Keep the medicine in the original container until use.
Safety	Keep Cardinol LA strictly out of the reach of children.

Disposal Protocol

Do not use the medicine after the expiration date printed on the package. To dispose of expired or unused Cardinol LA, return the product to a pharmacist or a recognized drug take-back location. It must not be disposed of in household trash or flushed down the toilet, to comply with environmental regulations.